市場調查報告書
商品編碼
1368684
人類微生物組市場規模 - 按部位(消化道、肺)、應用(治療、診斷)、疾病(傳染病、胃腸道疾病)、產品(藥物、診斷測試、益生菌)和全球預測 2023-2032Human Microbiome Market Size - By Site (Digestive Tract, Lung), Application (Therapeutics, Diagnostics), Disease (Infectious Diseases, Gastrointestinal Diseases), Product (Drugs, Diagnostic Tests, Probiotics) & Global Forecast 2023-2032 |
在全球優先考慮該領域研究的資助計劃和政府計劃不斷增加的推動下,2023 年至 2032 年間,全球人類微生物組市場佔有率將以 25.4% 的年複合成長率成長。微生物組研究的財政支持可加速科學進步,從而促進創新療法和診斷工具的開發。
2022 年7 月,杜蒙特-加州大學洛杉磯分校移植中心獲得了總計1150 萬美元的聯邦政府撥款,用於支持研究工作,其目標是延長捐贈器官的生存能力並提高移植受者的整體健康狀況和壽命。這些贈款一筆由美國國立衛生研究院提供,另一筆由國防部提供,致力於提高肝臟移植以及手部和臉部移植的效果。這些投資吸引了製藥和生物技術公司,促進了合作並擴大了市場。強調了解微生物組在健康和疾病中的作用,使人類微生物組產業在未來幾年顯著成長。
整個人類微生物組市場根據地點、應用、疾病、產品和地區進行分類。
到 2032 年,診斷領域可能會以可觀的成長率擴張。人們日益認知到微生物組在健康和疾病中發揮的重要作用,從而推動了對人類微生物組診斷的需求。研究人員和醫療保健專業人員越來越認知到,個別微生物組的組成可以為各種健康狀況提供有價值的見解,包括胃腸道疾病、自體免疫疾病,甚至心理健康問題。因此,人們對基於微生物組的診斷越來越感興趣,從而產生了對先進測試和分析方法的需求。
到 2032 年,益生菌細分市場可能會佔據一定的人類微生物組產業佔有率。人類微生物組益生菌由於其支持腸道健康和整體福祉的潛力而需求量很大。這些益生菌含有有益微生物,可以幫助維持腸道微生物組的平衡,而腸道微生物組與從消化到免疫功能等健康的各個方面越來越相關。尋求自然方法來改善健康的消費者正在轉向微生物益生菌,這為這些產品創造了強勁的市場需求。
由於多種因素,亞太地區人類微生物組產業正在不斷擴張。人們越來越認知到微生物組在健康中發揮的關鍵作用,這推動了對基於微生物組的產品和服務的需求。此外,慢性健康狀況的增加激發了人們對微生物組研究和治療的興趣。此外,該地區不斷增加的醫療基礎設施和研究投資進一步促進了亞太地區人類微生物組產業的成長。
Global Human Microbiome Market share will grow at 25.4% CAGR between 2023 and 2032, driven by the increasing funding initiatives and government programs worldwide prioritizing research in this field. Financial support for microbiome research accelerates scientific advancements, leading to the development of innovative therapies and diagnostic tools.
In July 2022, the Dumont-UCLA Transplant Center secured a combined $11.5 million in federal government grants to support research endeavors with the goal of extending the viability of donated organs and enhancing the overall health and longevity of transplant recipients. These grants, one provided by the National Institutes of Health and the other by the Department of Defense, are dedicated to advancing the outcomes of liver transplantation and hand and face transplantation. These investments attract pharmaceutical and biotechnology companies, fostering collaborations and expanding the market. The emphasis on understanding the role of the microbiome in health and disease positions the human microbiome industry for significant growth in the coming years.
The overall human microbiome market is segregated based on site, application, disease, product, and region.
The diagnostics segment could expand at a decent growth rate through 2032. The demand for human microbiome diagnostics is propelled by the growing awareness of the significant role the microbiome plays in health and disease. Researchers and healthcare professionals are increasingly recognizing that the composition of an individual's microbiome can provide valuable insights into various health conditions, including gastrointestinal disorders, autoimmune diseases, and even mental health issues. As a result, there's a rising interest in microbiome-based diagnostics, creating a demand for advanced testing and analysis methods.
The probiotics segment could capture a modest human microbiome industry share by 2032. Human microbiome probiotics are in high demand due to their potential to support gut health and overall well-being. These probiotics contain beneficial microorganisms that can help maintain a balanced gut microbiome, which is increasingly linked to various aspects of health, from digestion to immune function. Consumers seeking natural ways to improve their health are turning to microbiome probiotics, creating a strong market demand for these products.
Asia Pacific human microbiome industry is expanding due to several factors. A growing awareness of the pivotal role the microbiome plays in health is driving demand for microbiome-based products and services. Besides, the rise in chronic health conditions has spurred interest in microbiome research and therapies. Moreover, the region's increasing healthcare infrastructure and research investments further facilitate the growth of the human microbiome industry in the Asia Pacific.